CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation

Annals of Translational Medicine

Volumn 4, Issue 16, 2016, Pages

  Xu, Yang ^a,b   Dong, Hongxia ^a,c   Ge, Changhui ^a   Gao, Yan ^a   Liu, Haifeng ^b   Li, Weiguang ^a   Zhang, Chenggang ^a,d  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Inflammatory; Nuclear factor kappa B (NF B); Toll like receptor (TLR); Ulcerative colitis (UC)

Indexed keywords

ENTOLIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH PROTECTION; ULCERATIVE COLITIS;

EID: 85006219657     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2016.08.25     Document Type: Article

References (39)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
2. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-5.
3. Yamamoto-Furusho JK, Uscanga LF, Vargas-Alarcón G, et al. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. Hum Immunol 2003;64:119-23.
4. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011;17:3204-12.
5. Yang Y, He J, Suo Y, et al. Tauroursodeoxycholate improves 2,4,6-trinitrobenzenesulfonic acid-induced experimental acute ulcerative colitis in mice. Int Immunopharmacol 2016;36:271-6.
6. Satish Kumar CS, Kondal Reddy K, Reddy AG, et al. Protective effect of Lactobacillus plantarum 21, a probiotic on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. Int Immunopharmacol 2015;25:504-10.
7. Sakthivel KM, Guruvayoorappan C. Amentoflavone inhibits iNOS, COX-2 expression and modulates cytokine profile, NF-κB signal transduction pathways in rats with ulcerative colitis. Int Immunopharmacol 2013;17:907-16.
8. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-30.
9. Fukuzawa N, Petro M, Baldwin WM 3rd, et al. A TLR5 agonist inhibits acute renal ischemic failure. J Immunol 2011;187:3831-9.
10. Burdelya LG, Gleiberman AS, Toshkov I, et al. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for headand-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:228-34.
11. Yoon SI, Kurnasov O, Natarajan V, et al. Structural basis of TLR5-flagellin recognition and signaling. Science 2012;335:859-64.
12. Krivokrysenko VI, Shakhov AN, Singh VK, et al. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther 2012;343:497-508.
13. Chow CP, Faqi AS. Developmental toxicity study of CBLB502 in Wistar rats. Reprod Toxicol 2014;46:12-9.
14. Leigh ND, Bian G, Ding X, et al. A flagellin-derived tolllike receptor 5 agonist stimulates cytotoxic lymphocytemediated tumor immunity. PLoS One 2014;9:e85587.
15. Burdelya LG, Brackett CM, Kojouharov B, et al. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A 2013;110:E1857-66.
16. Li W, Ge C, Yang L, et al. CBLB502, an agonist of Tolllike receptor 5, has antioxidant and scavenging free radicals activities in vitro. Int J Biol Macromol 2016;82:97-103.
17. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
18. Yang Xu, Haifeng Liu, Department of Gastroenterology, et al. Preparation of a mouse model of TNBS-induced ulcerative colitis: technology improvement and optimal dose exploration. World Chinese Journal of Digestology 2012;20:106-12.
19. Watkins PE, Warren BF, Stephens S, et al. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997;40:628-33.
20. Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin Biol Ther 2003;3:725-31.
21. Rembacken BJ, Snelling AM, Hawkey PM, et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
22. Ochsenkühn T, D'Haens G. Current misunderstandings in the management of ulcerative colitis. Gut 2011;60:1294-9.
23. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62.
24. Gaffney PR, Doyle CT, Gaffney A, et al. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995;90:220-3.
25. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999;94:1551-5.
26. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
27. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005;128:825-32.
28. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960-5.
29. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
30. Carter MJ, di Giovine FS, Jones S, et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001;48:461-7.
31. Hibi T, Ohara M, Watanabe M, et al. Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis. Gut 1993;34:788-93.
32. Raab Y, Gerdin B, Ahlstedt S, et al. Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut 1993;34:1203-6.
33. Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010;45:999-1007.
34. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20.
35. Zeng H, Wu H, Sloane V, et al. Flagellin/TLR5 responses in epithelia reveal intertwined activation of inflammatory and apoptotic pathways. Am J Physiol Gastrointest Liver Physiol 2006;290:G96-G108.
36. Vijay-Kumar M, Gewirtz AT. Flagellin: key target of mucosal innate immunity. Mucosal Immunol 2009;2:197-205.
37. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167:1882-5.
38. de Zoete MR, Keestra AM, Wagenaar JA, et al. Reconstitution of a functional Toll-like receptor 5 binding site in Campylobacter jejuni flagellin. J Biol Chem 2010;285:12149-58.
39. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Tolllike receptor 5. Nature 2001;410:1099-103.